Designing circulating tumor DNA-based interventional clinical trials in oncology

Circulating tumor (ct) DNA is a powerful tool that can be used to track cancer beyond a single snapshot in space and time. It has potential applications in detecting minimal residual disease and predicting relapse, in selecting patients for tailored treatments, and in revealing mechanisms of respons...

Descripción completa

Detalles Bibliográficos
Autores principales: Araujo, Daniel V., Bratman, Scott V., Siu, Lillian L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Comment
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6474042/
https://www.ncbi.nlm.nih.gov/pubmed/31003596
http://dx.doi.org/10.1186/s13073-019-0634-x
_version_ 1783412565033877504
author Araujo, Daniel V.
Bratman, Scott V.
Siu, Lillian L.
author_facet Araujo, Daniel V.
Bratman, Scott V.
Siu, Lillian L.
author_sort Araujo, Daniel V.
collection PubMed
description Circulating tumor (ct) DNA is a powerful tool that can be used to track cancer beyond a single snapshot in space and time. It has potential applications in detecting minimal residual disease and predicting relapse, in selecting patients for tailored treatments, and in revealing mechanisms of response or resistance. Here, we discuss the incorporation of ctDNA into clinical trials.
format Online
Article
Text
id pubmed-6474042
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-64740422019-04-24 Designing circulating tumor DNA-based interventional clinical trials in oncology Araujo, Daniel V. Bratman, Scott V. Siu, Lillian L. Genome Med Comment Circulating tumor (ct) DNA is a powerful tool that can be used to track cancer beyond a single snapshot in space and time. It has potential applications in detecting minimal residual disease and predicting relapse, in selecting patients for tailored treatments, and in revealing mechanisms of response or resistance. Here, we discuss the incorporation of ctDNA into clinical trials. BioMed Central 2019-04-19 /pmc/articles/PMC6474042/ /pubmed/31003596 http://dx.doi.org/10.1186/s13073-019-0634-x Text en © The Author(s). 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Comment
Araujo, Daniel V.
Bratman, Scott V.
Siu, Lillian L.
Designing circulating tumor DNA-based interventional clinical trials in oncology
title Designing circulating tumor DNA-based interventional clinical trials in oncology
title_full Designing circulating tumor DNA-based interventional clinical trials in oncology
title_fullStr Designing circulating tumor DNA-based interventional clinical trials in oncology
title_full_unstemmed Designing circulating tumor DNA-based interventional clinical trials in oncology
title_short Designing circulating tumor DNA-based interventional clinical trials in oncology
title_sort designing circulating tumor dna-based interventional clinical trials in oncology
topic Comment
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6474042/
https://www.ncbi.nlm.nih.gov/pubmed/31003596
http://dx.doi.org/10.1186/s13073-019-0634-x
work_keys_str_mv AT araujodanielv designingcirculatingtumordnabasedinterventionalclinicaltrialsinoncology
AT bratmanscottv designingcirculatingtumordnabasedinterventionalclinicaltrialsinoncology
AT siulillianl designingcirculatingtumordnabasedinterventionalclinicaltrialsinoncology

Ejemplares similares